Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

Researchers have identified two experimental medications that may be able to promote myelin repair in people with MS, a study ...

VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...

EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.

The project builds on earlier research involving a compound called indazole chloride, known for promoting remyelination and modulating the immune system in mouse models of MS. While effective, ...

A well-established diabetes drug alleviated brain inflammation in a female mouse model of multiple sclerosis, suggesting the ...

Restricted coverage of medications for relapsing-remitting multiple sclerosis (MS) was associated with a higher risk for relapse, a new study showed. Patients with MS enrolled in Medicare Advantage ...

The lab is using AI to analyze complex biomedical data to improve drug development for many diseases, including MS and ...

Zeposia (ozanimod) is a prescription drug used to treat certain forms of multiple sclerosis (MS) in adults. Zeposia is a brand-name drug and is not currently available in a generic version. Zeposia ...